Cynata making stem cells for therapeutic use
28 Apr 2015 - Cynata Therapeutics Limited (ASX:CYP) Managing Director and CEO Ross Macdonald details plans to commercialise its therapeutic technology.
By: Finance News Network
Posted: April 29, 2015 at 2:46 am
Cynata making stem cells for therapeutic use
28 Apr 2015 - Cynata Therapeutics Limited (ASX:CYP) Managing Director and CEO Ross Macdonald details plans to commercialise its therapeutic technology.
By: Finance News Network
Posted: April 29, 2015 at 2:46 am
Short on Stem Cell Research
Hey guys!! Leon from international junkies here! This is our first post ever, and I know we probably should have uploaded our introduction video first, but we hope you like this. My friend,...
By: International Junkies
Posted: April 28, 2015 at 12:48 am
Cellogica Stem Cell Review Gain A Healthy And Vibrant Looking Skin With Cellogica
Read Terms And Condition First Before Claiming Your Cellogica Stem Cell Risk Free trial: http://skincarebeautyshop.com/ Read More About Cellogica Stem Cell Here: http://skincareinfo4u.com/cellogic.
By: Mil.Inc
Read more:
Cellogica Stem Cell Review Gain A Healthy And Vibrant Looking Skin With Cellogica - Video
Posted: April 27, 2015 at 9:51 pm
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100:3983-3988
Annaloro C, Onida F, Saporiti G, Lambertenghi Deliliers G (2011) Cancer stem cells in hematological disorders: current and possible new therapeutic approaches. Curr Pharm Biotechnol 12:217-225
Augello A, Kurth TB, De Bari C (2010) Mesenchymal stem cells: a perspective from in vitro cultures to in vivo migration and niches. Eur Cells Mat 20:121-133
Baba M, Ma BY, Nonaka M, Matsuishi Y, Hirano M, Nakamura N, Kawasaki N, Kawasaki N, Kawasaki T (2007) Glycosylation-dependent interaction of Jacalin with CD45 induces T lymphocyte activation and Th1/Th2 cytokine secretion. J Leukoc Biol 81:1002-1011
Badcock G, Pigott C, Goepel J, Andrews PW (1999) The human embryonal carcinoma marker antigen TRA-1-60 is a sialylated keratin sulfate proteoglycan. Cancer Res 59:4715-4719
Baldus SE, Zirbes TK, Hanisch FG, Kunze D, Shafizadeh ST, Nolden S, Mnig SP, Schneider PM, Karsten U, Thiele J, Hlscher AH, Dienes HP (2000) Thomsen-Friedenreich (TF) antigen presents as a prognostic factor in colorectal carcinoma: a clinico-pathological study including 264 patients. Cancer 88:1536-1543
Barrow H, Tam B, Duckworth CA, Rhodes JM, Yu L-G (2013) Suppression of core-1 Gal-transferase is associated with reduction of TF and reciprocal increase of Tn, sialyl-Tn and core-3 glycans in human colon cancer cells. PLoS One 8:e59792 PublisherFullText
Basso G, Timeus F (1998) Cytofluorimetric analysis of CD34 cells. Bone Marrow Transplant Suppl 5:S17-S20
Battula VL, Shi Y, Evans KW, Wang R-Y, Spaeth EL, Jacamo RO, Guerra R, Sahin AA, Marini FC, Hortobagyi G, Mani SA, Andreeff M (2012) Ganglioside GD2 identifies breast cancer stem cells and promotes tumorigenesis. J Clin Invest 122:2066-2078
Beuth J, Ko HL, Schirrmacher V, Uhlenbruck G, Pulverer G (1988) Inhibition of liver tumor cell colonization in two animal tumor models by lectin blocking with D-galactose or arabinogalactan. Clin Exp Metastasis 6:115-120
Continued here:
SpringerPlus | Full text | What makes cancer stem cell ...
Posted: April 27, 2015 at 9:50 pm
Dr. Mark A. Foglietti (pronouned 'Fuhl-yetti) was born Steubenville, Ohio and raised in Mingo Junction, Ohio. He attended Ohio State University in Columbus, Ohio where he received his Bachelors of Science Degree and completed one year of post-graduate work in microbiology and virology. He then went to Medical School at Ohio University, where he currently serves as a Clinical Professor in Plastic and Reconstructive Surgery. The Ohio University College of Osteopathic Medicine is nationally recognized as one of the top physician training programs in the country.
Dr. Foglietti returned to the Columbus area to fulfill a one-year rotating internship at Doctor's Hospital where he stayed to finish his training in general surgery. As a general surgery resident, he was accepted into the plastic surgery residency at The Plastic Surgery Institute of Des Moines Iowa, under the direction of the internationally acclaimed plastic surgeon Dr. James O. Stallings, M.D. During his time in Iowa, Dr. Foglietti served as a resident and as the Chief Resident of the program. To further enhance his plastic and reconstructive surgery knowledge, he completed an additional fellowship in cosmetic surgery and reconstructive surgery of the breast, in Cleveland Ohio under the direction of Dr. Melvyn I. Dinner and Dr. J. Sheldon Artz.
With 17 years of higher education, medical, and surgical training behind him, Dr. Foglietti started his career by joining Drs. Dinner and Artz at The Center for Plastic Surgery. He soon became board certified in both plastic and reconstructive surgery and in general surgery, later co-founding the Woodlands Center for Plastic Surgery, located in Sagamore Hills, Ohio.
Dr. Foglietti founded the Cosmetic Surgery Institute in Beachwood, Ohio in 2000. He established himself as an educator and leader in his field both locally and nationally. He is a member of The American Osteopathic Association, The American Medical Association and their respective local organizations. He is a past president and board member of the Cleveland Academy of Osteopathic Medicine, and serves nationally on the Board of Governors for The American College of Osteopathic Surgeons. As a Fellow of the A.C.O.S., he is also a past President of the Plastic and Reconstructive Surgery Discipline, and serves nationally as a board examiner. Dr. Foglietti was the Chief of staff, and Chief of Plastic Surgery at Mt. Sinai Medical Center East. He is also Director of the plastic and reconstructive surgery residency at the Cleveland Clinic Health System Hospital, Meridia Southpointe.
For over a decade, Dr. Foglietti has published numerous papers in a variety of internationally recognized medical and scientific journals. Keeping up to date on all of the latest surgical techniques, and newest technology, Dr. Foglietti has been given significant local and national television exposure, (ABC, CBS, NBC, FOX, CNN, and The Discovery Channel) for bringing new advancements to the Cleveland medical market. He has also been recognized for his advanced treatment of burn victims internationally and for his assistance in the treatment of the Afghanistan Freedom Fighters, for which he received an award from Washington D.C. in 1988.
Dr. Foglietti has been featured in Cleveland magazine, Northern Ohio Live, The Plain Dealer, The Canton Repository, as well as a number of other newspapers for his improvements in plastic and reconstructive surgery. As an inventor, Dr. Foglietti holds three U.S. Patents on improved breast implants for surgical use. He strives to remain on the cutting edge of medicine to serve his patients in the most up-to-date, personalized, and holistic manner possible. Dr. Foglietti has also recently received a registered trademark for the Foglietti Natural Vector Facelift Technique from the US Patent and Trademark Office in Washington DC in November 09.
Dr. Foglietti has been recognized for treatment of the Haiti earthquake victims for a medical mission in February 2010. He has also completed medical missions to Columbia in pediatric burn surgery, 2013 and 2014. He is a recipient of the Ohio University Hertiage College of Ostepathic Medicine's Distinguished service award. He is also national faculty for Allergan Corporation and considered one of the elite injectors in the United States. He is the co founder of the Ohio Stem Cell Treatment Center of Cleveland, Ohio. http://www.ohiostemcelltreatmentcenter.com
Vision Statement: To be internationally recognized for the highest quality cosmetic surgery and aesthetic services.
Mission Statement:
To provide exemplary care through technology, skills and attitudes which create an exceptional experience that fosters lasting loyalty.
Go here to see the original:
Dr. Foglietti | Ohio Stem Cell Treatment Center of Cleveland
Posted: April 27, 2015 at 9:48 pm
Brigham and Womens Hospital cardiac stem cell researcher Piero Anversa along with collaborator Annarosa Leri (pictured) are suingboth the hospital and Harvard Medical School as well as leaders at the institutions over a research misconduct investigation focused on Anversa and Leri.
Boston Globe reporter Carolyn Johnson has been covering Anversa and for backgroundon this new lawsuit she wrote:
Work overseen by Dr. Piero Anversa, a professor of anesthesia at the Brigham, was thrust into the spotlight earlier this year whenone of his papers investigating the hearts ability to regenerate itself was retractedafter an internal probe revealed it had used compromised data. Another study overseen by Anversa that reported on an early clinical trial testing the use of heart stem cells in patients wasflaggeddue to the ongoing investigation into the integrity of certain data.
The issues with these studies prompted Brigham and Harvard to start investigating.
A key point of the suit against Harvard alleges that problems such as data manipulation inthe publications were the sole responsibility of a former scientist in the Anversa lab,Dr. Jan Kajstura, and that Anversa and Leri arenot responsible for these issues.
Remarkably, according to the Globe the investigation at the heart of the suit apparently examined and may have found evidence of alleged misconduct in more than 15 papers on whichthese scientists were authors.
The suit, which can be read here, asserts that the investigation has harmed the careers of Anversa and Leri. For example, the suits argues that the defendants:
have caused and are causing ongoing harm toPlaintiffs Dr. Piero Anversa and Dr. Annarosa Leris (collectively, Plaintiffs) reputations andcareers by conducting a procedurally and legally flawed investigation into alleged researchmisconduct at a Brigham laboratory
There is a great deal of interesting information in the lawsuit document itself. For example, it provides a window into how Harvard investigates matters. It also details three initial allegations of misconduct against Anversa and Leri:
Follow this link:
Harvard Sued Over Stem Cell Paper Misconduct Investigation ...
Posted: April 27, 2015 at 9:40 pm
Hiro Nakauchi Definitive and Stem Cell Gene Therapy for Child Health: Stanford Childx Conference
Hiro Nakauchi discusses new stem cell therapies at the inaugural Childx Conference, 2015. Childx is a dynamic, TED-style conference designed to inspire innovation that improves pediatric and...
By: Stanford
See the rest here:
Hiro Nakauchi Definitive and Stem Cell & Gene Therapy for Child Health: Stanford Childx Conference - Video
Posted: April 27, 2015 at 9:40 pm
Sean Wu Definitive Stem Cell and Gene Therapy for Child Health: Stanford Childx Conference
Sean Wu discusses his work engineering stem cells to cure heart disease at the inaugural Childx Conference, 2015. Childx is a dynamic, TED-style conference designed to inspire innovation that...
By: Stanford
See the original post here:
Sean Wu Definitive Stem Cell and Gene Therapy for Child Health: Stanford Childx Conference - Video
Posted: April 27, 2015 at 12:43 pm
Researchers find that brain activity promotes the growth of brain cancer
Stanford Institute for Stem Cell Biology and Regenerative Medicine researcher Michelle Monje, MD, PhD, has found that normal brain activity creates factors that promote the growth of a brain...
By: institutesofmedicine
Read more:
Researchers find that brain activity promotes the growth of brain cancer - Video
Posted: April 27, 2015 at 12:42 pm
Nadia Rosenthal Definitive Stem Cell and Gene Therapy for Child Health: Stanford Childx Conference
Nadia Rosenthal discusses the advances in regeneration and the future of regenerative health at the inaugural Childx Conference, 2015. Childx is a dynamic, TED-style conference designed to...
By: Stanford
Original post:
Nadia Rosenthal Definitive Stem Cell and Gene Therapy for Child Health: Stanford Childx Conference - Video